| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. | Cancer Res | 2007 | 1.40 |
| 2 | Modeling a lethal prostate cancer variant with small-cell carcinoma features. | Clin Cancer Res | 2011 | 1.15 |
| 3 | Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. | BMC Med Genomics | 2009 | 1.11 |
| 4 | Epigenetics in prostate cancer. | Prostate Cancer | 2011 | 0.92 |
| 5 | Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. | PLoS One | 2012 | 0.92 |
| 6 | Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. | Urol Oncol | 2009 | 0.87 |
| 7 | Hypomethylating agents for urologic cancers. | Future Oncol | 2011 | 0.77 |